Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Antiviral Res. 2018 Apr 27;155:12–19. doi: 10.1016/j.antiviral.2018.04.019

Fig. 1. Identification of a potent anti-DENV compound and an analog with increased activity.

Fig. 1.

(A) Structure of VGTI-A3 and its analog, VGTI-A3–03 (B) and a previously identified anti-DENV compound, ST-148 (C). (D) HEK293 cells were infected with DENV at MOI = 0.1 ffu/cell + increasing concentrations of VGTI-A3 or VGTI-A3–03 (DMSO, 30 nM, 100 nM, 300 nM, 1uM, 3uM, 10uM, 30uM). Supernatants were collected at 3d pi, and assayed for infectious virus by focus forming assay (ffa). Calc LogP, IC90, VLR, and CC50 were calculated as described in Materials and Methods. (E) HEK293 cells were infected with indicated viruses at MOi = 0.1 ffu/cell in the presence of DMSO (white) or 1uM VGTI-A3 (grey) or VGTI-A3–03 (black). At 3 days pi, supernatants were collected and assayed by focus forming assay. Data are presented as mean ± SEM in triplicate.